Drug Safety and PV Services

When patient safety is of the utmost importance, Sponsors trust MMS as their go-to CRO.

We are very impressed with the quality of the MMS deliverables. Excellent improvement proposals!
Oncology Clinical Lead
Top 5 Pharma

MMS provides comprehensive solutions to meet the pharmacovigilance and drug safety needs of the pharmaceutical industry today. An efficient, adaptable model enables increased productivity, enhances safety monitoring external reporting, and offers Sponsors more time to focus on strategy rather than day-to-day processing activities.

Comprehensive safety services across all phases of clinical research include:

  • Implementation and Management of safety databases, including data migration services
  • Medical safety monitoring
  • 24/7 case management
  • Serious Adverse Event (SAE) management and expedited reporting
  • Ad hoc safety analyses and risk management
  • Signal detection
  • Annual reports, periodic safety update reports (PSURs), and expert reports
  • Labeling/CCDS support
  • Literature reviews

Medical Monitoring Services
Medical monitoring experts at MMS provide medical reviews and oversight of clinical trial activities across all phases of clinical research, including first-in-human trials. Experienced medical staff bring a practical and real-world clinical perspective to assist study and sponsor teams with every aspect of subject safety. This includes ongoing collaboration with clinical trial investigators, assisting with safety event reporting and the analysis, interpretation of efficacy, safety, and outcomes data.

The MMS medical monitoring team adds value throughout the clinical trial process, including the evaluation and determination of the clinical implications of the study results.

Suggested For You

news

March 19th, 2025

MMS REMS-focused Technology bolsters Full-Service REMS Solutions

webinar

April 30th, 2025

Advancing Clinical Development with Innovative Trial Design and Regulatory Strategies

perspectives

March 6th, 2025

Overview of FDA Guidance for Industry on Assessment of Ovarian Toxicity in Premenopausal Adults During Development for Oncologic Products

webinar

March 25th, 2025

Overcoming NDA/BLA Submission Challenges: Practical Strategies for Success

perspectives

February 13th, 2025

Helping European Drug Development Companies Succeed in the US Market

news

February 12th, 2025

MMS Acquires Exploristics and KerusCloud Simulation Platform to Expand Biostatistics and Data Science Capabilities as a Global Data-Focused CRO

perspectives

January 30th, 2025

Post-PDUFA VII Updates: FDA Meetings Public Workshop & Lessons Learned

perspectives

January 21st, 2025

REMS Modifications and Revisions: A Retrospective from the Past 12 Months

regulatory intelligence

January 17th, 2025

The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development

regulatory intelligence

January 17th, 2025

New FDA Protocol Deviation Guidance:  Planning for the Things That Don’t Go According to Plan

perspectives

January 9th, 2025

How to Create Efficiencies When Creating Simultaneous NDA and MAA Submissions for the FDA and EMA

perspectives

January 2nd, 2025

Informed Consent in Clinical Research: Understanding its Significance and Sponsor Obligations